# HIV/AIDS global response ## What this driver is The HIV/AIDS global response is the continuing architecture that converted a fatal retroviral pandemic into a chronic, treatable infection for people who can reach antiretroviral therapy (ART), while leaving key populations and under-funded programmes behind. It is not a unique Factrail death total, not a 1980s mood, and not [access to essential medicines](/drivers/access-to-essential-medicines) as a general essential-drugs meter. This node is the HIV-specific response: testing, ART, prevention, TRIPS flexibilities, and the political declarations that funded or rationed them. This driver is not [COVID-19 pandemic](/drivers/covid-19-pandemic), not [vaccine accessibility](/drivers/vaccine-accessibility), and not [pandemic preparedness](/drivers/pandemic-preparedness). COVID-19 disrupted HIV clinics; that is a neighbouring shock, not a twin. It is not ukraine-war. The legal-political core is the 2001 UN General Assembly Special Session Declaration of Commitment on HIV/AIDS, the Doha Declaration on the TRIPS Agreement and Public Health (14 November 2001), PEPFAR (United States Leadership Against HIV/AIDS, Tuberculosis and Malaria Act, 27 May 2003), the Global Fund, UNAIDS 90-90-90 (2014) then 95-95-95 targets, and later UNGA high-level political declarations (2016, 8 June 2021). A target is not coverage. It applies worldwide from the 1981 CDC reports through the ART era. ## Mechanism The response moves welfare through named channels. First, ART scale-up. World Bank WLD SH.HIV.ARTC.ZS — people living with HIV on ART as a share of those living with HIV — rose from 2% (2003, PEPFAR’s year) to 77% (2024). That is a coverage meter, not an incidence meter, and not a death total. UNAIDS still publishes separate infection and AIDS-death estimates. Those estimates remain named instruments. This page does not invent Contribution.size. Second, intellectual-property and generic manufacture. Doha 2001 stated that TRIPS should not prevent Members from protecting public health. Compulsory licensing and Indian generic production changed prices. A declaration is not a completed licence in every country. Third, vertical programmes and conditionality. PEPFAR and the Global Fund built clinics, commodities, and reporting. They also imported earmarks, abstinence-era rules, and later funding fights. Fourth, key-population exclusion. Criminalisation of same-sex relations, drug use, and sex work keeps people off the 95-95-95 cascade. Coverage averages hide that. An average is not a key-population census. Fifth, COVID-era interruption. Clinic closures and stock-outs in 2020–21 slowed the ART climb (67% in 2020, 70% in 2021). Timing is weeks for a stock-out and years for a 95-95-95 miss. A later long-acting CAB-LA scale-up with a date would be a new fact. It would not twin this driver. ## Evidence base The best evidence is UNGA/WTO texts plus the World Bank ART series (UNAIDS/WHO underlying). World Bank WLD SH.HIV.ARTC.ZS (https://api.worldbank.org/v2/country/WLD/indicator/SH.HIV.ARTC.ZS?format=json&date=2000:2024&per_page=100): 1% (2000), 2% (2003), 24% (2010), 47% (2015), 67% (2020), 73% (2022), 77% (2024). Meter values are that percentage divided by 100. Doha is WT/MIN(01)/DEC/2 (https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm). PEPFAR is Public Law 108-25. The 2021 political declaration is A/RES/75/284 (https://www.unaids.org/en/resources/documents/2021/2021_political-declaration-on-hiv-and-aids). Evidence is strongest for a signed declaration and a World Bank/UNAIDS coverage point. It is weaker for any unique 1980s death coefficient. It is weakest where a 95-95-95 slogan is asked to prove key-population coverage. ## Effect on welfare indicators This driver, when ART actually reaches people, is a first-order channel into adult and child survival. - [Under-five mortality rate](/indicators/ph-under-five-mortality-global): direction lower deaths when paediatric ART and prevention of vertical transmission scale. Horizon: years. Confidence: high where programmes ran; the series is lower-is-better, so strengthening the response (more ART) is welfare-positive — impact type strengthening with positive welfare direction on a lower-is-better series means the *response* reduces deaths. This page codes the DII as the response weakening under-five mortality. - [Life expectancy at birth](/indicators/health-welfare-021-life-expectancy-at-birth): direction higher period LE where ART scaled in high-prevalence countries. Horizon: years. Confidence: high for southern Africa’s post-2005 LE recovery as a documented neighbouring observation; low for a unique global coefficient. Strengthening the response strengthens a higher-is-better series. - [Universal health coverage service coverage index](/indicators/care-welfare-041-universal-health-coverage-uhc-service-coverage-index-2025-methodology): direction higher coverage when HIV testing and ART are in the UHC package. Horizon: years. Confidence: medium. This is not a twin of access to essential medicines. Missing coefficients stay missing. ## Interactions and contested points HIV response interacts with access to essential medicines, vaccine accessibility only if an HIV vaccine arrives, [health-system capacity](/drivers/health-system-capacity), and COVID-19 pandemic as a 2020–21 shock. Reinforcement is obvious when a TRIPS waiver fight and a clinic stock-out hit the same country. Offsetting is the claim that 77% ART coverage means AIDS is over. UNAIDS still records new infections. Coverage is not elimination. The strongest competing view is that ART coverage is an *outcome* of the response, not the driver, so the meter is circular. The competing defence is the same as SPAR on preparedness: a disclosed official series that moves with the architecture, with TRIPS, PEPFAR, and UNGA texts as the dated acts. A second competing view is that PEPFAR is US charity and should not sit on a global driver. PEPFAR is one instrument among Doha, the Global Fund, and UNGA declarations. It is not the whole node. Established: Doha 14 November 2001; PEPFAR 27 May 2003; World Bank ART 2% (2003) to 77% (2024); 90-90-90/95-95-95 as targets, not achieved uniformly. Not established: a unique Factrail AIDS-death total, or that 77% coverage is 95-95-95. A later UNGA HLM with a date would be a new fact. It would not twin this driver. ## Dated facts - 2024: PURPOSE 1 interim analysis: twice-yearly lenacapavir showed 100% efficacy for PrEP in cisgender women. https://factrail.ai/facts/purpose1-lenacapavir-prep-100-efficacy-2024. - 2022: FDA approved Sunlenca (lenacapavir) for multidrug-resistant HIV. https://factrail.ai/facts/fda-sunlenca-lenacapavir-mdr-hiv-2022. - 2022: FDA approved Sunlenca (lenacapavir), first HIV capsid inhibitor, for multidrug-resistant HIV. https://factrail.ai/facts/fda-sunlenca-lenacapavir-approval-2022. - PEPFAR-supported antiretroviral therapy reached about 20 million people by FY2022. https://factrail.ai/facts/pepfar-20-million-on-art-fy2022. - 2022: Global Fund Seventh Replenishment secured record multi-billion-dollar pledges. https://factrail.ai/facts/global-fund-seventh-replenishment-2022. - 2021: FDA approved Apretude, first long-acting injectable HIV PrEP option. https://factrail.ai/facts/fda-apretude-cabotegravir-prep-2021. - 2021: FDA approved Cabenuva, first complete long-acting injectable HIV treatment regimen. https://factrail.ai/facts/fda-cabenuva-long-acting-treatment-2021. - 2020: UNAIDS proposed bold 95-95-95 HIV testing and treatment targets for 2025. https://factrail.ai/facts/unaids-95-95-95-targets-2020. - 2020: UNAIDS proposed 95-95-95 and related 2025 people-centred HIV targets. https://factrail.ai/facts/unaids-95-95-95-targets-proposed-2020. - 2020: WHO warned COVID-19 severely disrupted access to HIV medicines and services. https://factrail.ai/facts/who-covid19-hiv-arv-disruption-2020. - 2019: FDA approved Descovy for HIV PrEP excluding receptive vaginal sex risk. https://factrail.ai/facts/fda-descovy-prep-approval-2019. - 2019: WHO recommended dolutegravir as preferred first-line HIV treatment for all populations. https://factrail.ai/facts/who-dolutegravir-preferred-first-line-2019. ## Methodology https://factrail.ai/methodology Canonical: https://factrail.ai/drivers/hiv-aids-response